A clinical validation study for Digistain’s novel, rapid, and cost-effective alternative to transcriptomic risk profiling in order to efficaciously predict disease-free survival has been published in the Springer Nature Journal of Breast Cancer Research & Treatment.
The landmark independent clinical study, authored by some of the leading names in breast cancer oncology and pathology demonstrated that Digistain’s breast cancer diagnostic technology is able to accurately predict patients at low risk of disease recurrence who may forgo adjuvant chemotherapy.
Clinical Study Parameters
- 801 patients with Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 – Negative (HER2) Primary Breast Cancer
- Patients with ≤3 positive lymph node breast cancer
- No adjuvant chemotherapy: Systemic endocrine therapy where appropriate
- Median follow up 12.7 years